The science is here. The money isn't.

That is the blunt summary of a structural problem that has been quietly draining economic value from British Columbia's life sciences sector for years. Founders spinning out of UBC's University-Industry Liaison Office, BC Cancer, and SFU are producing intellectual property that competes on any stage in the world. However, when it comes time to raise the $15- to $25-million Series A that turns a promising compound or platform into a company, they are boarding planes to Boston—and in many cases, they are not coming back.

Canadian life sciences venture investment reached approximately $2.1 billion in 2025, according to BDC Capital data. BC's share of that total was disproportionately small relative to the province's research output—under $400 million, a fraction of what comparable clusters in Toronto and Montreal attracted. Meanwhile, BC Cancer and UBC collectively filed over 120 patent applications in 2024–25. The research pipeline is full; the commercialization pipeline is leaking.

The Gap in Numbers

To understand why this matters, one must understand the mechanics of biotech financing. Early-stage seed and pre-seed capital—the money that gets a lab discovery to proof-of-concept—is relatively available in Vancouver. Angels, government grants through Genome BC, and federal programs through the National Research Council fill some of that gap. The problem is the next step.

Series A rounds in Canadian life sciences have a median size of roughly $15 to $25 million. That is the round that funds Phase 1 or Phase 2 clinical trials, builds out a regulatory affairs team, and starts turning a scientific hypothesis into a commercial asset. It requires investors who understand biotech timelines—five to ten years, high failure rates, massive upside—and who have the fund size to write meaningful cheques and follow on in later rounds.

Vancouver lacks enough of those investors. The two most active Canadian life sciences-focused venture capital firms—Amplitude Ventures and Lumira Ventures—are based in Montreal and Toronto, respectively. Both invest in BC companies, but their presence here is remote. There is no equivalent of Boston's Flagship Pioneering or San Francisco's ARCH Venture Partners operating out of a Gastown office. The sector-specialist capital that biotech founders need is concentrated elsewhere, and that geography has consequences.

Why Boston Wins the Close

It is not just about cheque size. Founders who have navigated this process describe a compounding disadvantage. US biotech investors—particularly those on the East Coast—possess decades of pattern recognition regarding FDA pathways, partnership structures with big pharma, and the talent markets that a growing biotech company needs to access. They have seen hundreds of companies at the Series A stage and move faster because their diligence is more efficient.

Vancouver investors, even sophisticated ones, often lack that specialization. A generalist tech investor who has backed software-as-a-service or fintech startups is not well-positioned to lead a $20-million biotech Series A. The risk profile, milestones, and exit pathways—such as trade sales to Pfizer or Roche, or a NASDAQ IPO—differ significantly from the typical Vancouver venture capital playbook.

The result is a familiar founder experience: raise a seed round locally, generate early data, then spend 12 to 18 months pitching Canadian investors who are interested but not quite ready to lead. Eventually, the founder lands a term sheet from a Boston or New York firm that has seen this stage of company a hundred times. By then, the company's legal structure has been redomiciled to Delaware, the CEO is splitting time between Vancouver and Cambridge, Massachusetts, and the long-term gravitational pull toward a full US relocation has begun.

What It's Costing BC

The economic stakes are significant. Life sciences companies that scale tend to be high-wage, long-duration employers. A biotech that raises a Series B and begins clinical-stage operations hires PhD scientists, regulatory specialists, clinical trial managers, and eventually a commercial team. Those are jobs that pay well above the provincial median and tend to stay put once established.

When a BC-origin company redomiciles and scales in Boston, those jobs go with it. The intellectual property—often developed with public funding through federal granting councils or provincial programs—generates returns that flow to US investors and employees. BC taxpayers funded the research infrastructure, but Boston captures the economic dividend.

Life Sciences BC's membership surveys have consistently flagged access to growth capital as the top structural challenge facing the sector. The organization represents over 200 member companies and has been vocal about the need for dedicated provincial and federal policy responses.

The Opportunity Inside the Problem

The gap is documented, and it will not resolve on its own. That creates a first-mover advantage for any Canadian investor willing to build genuine sector expertise in life sciences and deploy it in BC.

The deal flow is present. UBC's technology transfer office is one of the most active in Canada. BC Cancer's research programs in genomics and oncology are world-class. SFU's health sciences and biomedical engineering programs are producing spinout candidates. The raw material for a dozen fundable Series A companies exists in this city right now. The question is whether local capital is sophisticated and patient enough to lead those rounds.

Some players are beginning to move. Genome BC has expanded its venture investment activity, taking a more active role in bridging the gap between research commercialization and institutional venture capital. Federal programs through BDC Capital's life sciences mandate have also increased activity in the province. However, these are partial solutions. The ecosystem needs a dedicated, BC-based life sciences fund with the mandate and expertise to lead Series A rounds, rather than merely co-investing alongside US firms.

The provincial government has levers here, too. Quebec's success in building a life sciences cluster in Montreal involved sustained public investment in research infrastructure, tax incentives for clinical trial activity, and patient capital through provincial vehicles. BC has the research base that Quebec built over decades. The policy toolkit to retain the economic value of that research is well understood; the question is one of political will and urgency.

The Bigger Picture

Vancouver's tech ecosystem has matured significantly over the past decade, producing scaled companies in enterprise software, fintech, and cleantech. But life sciences operates on a different clock and requires different infrastructure. The bench-to-market journey for a drug or diagnostic is measured in years and decades, not months. The capital that funds it must be equally patient.

The founders navigating this gap—raising seed rounds in Vancouver, closing Series A rounds in Boston, and making difficult decisions about where to build—are acting rationally. They are going where the capital and expertise are. The question for Vancouver's investor community is whether it wants to be part of that story, or whether it is content to watch the upside leave on a flight to Logan Airport.

The science is not going anywhere. UBC and BC Cancer will continue to generate world-class intellectual property. The opportunity for local investors is to build the capital infrastructure that keeps the companies those discoveries create—and the jobs, the returns, and the ecosystem density that comes with them—rooted in BC.